UNSPSC 51172482: Taliglucerase alfa

Taliglucerase alfa is a biopharmaceutical medication developed. The drug is a recombinant glucocerebrosidase used to treat Gaucher's disease.

UNSPSC 51172482 Taliglucerase alfa (Commodity) does not reflect recent state and local procurement activity. Taliglucerase alfa is an enzyme replacement therapy used to treat Gaucher disease, a rare genetic disorder; the code names a single pharmaceutical product line. The recent-opportunities block contains no active solicitations for taliglucerase alfa or any other pharmaceutical product matched to this code. The block does include multiple recent pharmaceutical and medical-supply procurements—including Seminole County's 2026 naloxone and drug deactivation system purchase (IFB, due July 26, 2026), the City of Tucson Fire Department's 2026 BLS/ALS pharmaceuticals and vending-machine contract (RFP, due June 24, 2026), and Pinellas County's forensic drug-standards procurement (ITQ, due April 23, 2026)—but none of these opportunities target taliglucerase alfa or rare-disease therapeutics. The pharmaceutical and OTC product lines being actively solicited across state and local jurisdictions focus on emergency medical supplies, public health needs, forensic testing, and over-the-counter inventory, not orphan-disease treatments.

No state or local government purchasing activity under UNSPSC 51172482 is evident in the current opportunities block, and the code does not appear relevant to the scope of goods and services state and local jurisdictions are currently procuring. Bidders evaluating this code should not pursue it as an active market segment.